These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 27241174)

  • 21. Anti-atherosclerotic molecules targeting oxidative stress and inflammation.
    Adameova A; Xu YJ; Duhamel TA; Tappia PS; Shan L; Dhalla NS
    Curr Pharm Des; 2009; 15(27):3094-107. PubMed ID: 19754384
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Macrophage Membrane-Encapsulated Dopamine-Modified Poly Cyclodextrin Multifunctional Biomimetic Nanoparticles for Atherosclerosis Therapy.
    Zhu L; Zhong Y; Yan M; Ni S; Zhao X; Wu S; Wang G; Zhang K; Chi Q; Qin X; Li C; Huang X; Wu W
    ACS Appl Mater Interfaces; 2024 Jun; 16(25):32027-32044. PubMed ID: 38867426
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nitric oxide enhances the anti-inflammatory and anti-atherogenic activity of atorvastatin in a mouse model of accelerated atherosclerosis.
    Momi S; Monopoli A; Alberti PF; Falcinelli E; Corazzi T; Conti V; Miglietta D; Ongini E; Minuz P; Gresele P
    Cardiovasc Res; 2012 Jun; 94(3):428-38. PubMed ID: 22362817
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Anti-atherosclerotic effect of pioglitazone--the first evidence of the role of triglyceride/HDL ratio].
    Császár A
    Lege Artis Med; 2011 Feb; 21(2):105-11. PubMed ID: 21710708
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Macrophage Phenotype and Function in Different Stages of Atherosclerosis.
    Tabas I; Bornfeldt KE
    Circ Res; 2016 Feb; 118(4):653-67. PubMed ID: 26892964
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synergistic effect of liver X receptor activation and simvastatin on plaque regression and stabilization: an magnetic resonance imaging study in a model of advanced atherosclerosis.
    Giannarelli C; Cimmino G; Connolly TM; Ibanez B; Ruiz JM; Alique M; Zafar MU; Fuster V; Feuerstein G; Badimon JJ
    Eur Heart J; 2012 Jan; 33(2):264-73. PubMed ID: 21606082
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Atorvastatin inhibits the 5-lipoxygenase pathway and expression of CCL3 to alleviate atherosclerotic lesions in atherosclerotic ApoE knockout mice.
    Yang LX; Heng XH; Guo RW; Si YK; Qi F; Zhou XB
    J Cardiovasc Pharmacol; 2013 Aug; 62(2):205-11. PubMed ID: 23615158
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of Si-Miao-Yong-An on the stability of atherosclerotic plaque in a diet-induced rabbit model.
    Peng L; Li M; Xu YZ; Zhang GY; Yang C; Zhou YN; Li LJ; Zhang JP
    J Ethnopharmacol; 2012 Aug; 143(1):241-8. PubMed ID: 22750436
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pycnogenol attenuates atherosclerosis by regulating lipid metabolism through the TLR4-NF-κB pathway.
    Luo H; Wang J; Qiao C; Ma N; Liu D; Zhang W
    Exp Mol Med; 2015 Oct; 47(10):e191. PubMed ID: 26492950
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Weekly Treatment of 2-Hydroxypropyl-β-cyclodextrin Improves Intracellular Cholesterol Levels in LDL Receptor Knockout Mice.
    Walenbergh SM; Houben T; Hendrikx T; Jeurissen ML; van Gorp PJ; Vaes N; Olde Damink SW; Verheyen F; Koek GH; Lütjohann D; Grebe A; Latz E; Shiri-Sverdlov R
    Int J Mol Sci; 2015 Sep; 16(9):21056-69. PubMed ID: 26404254
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development of anti-atherosclerosis therapy based on the inflammatory and proliferative aspects of the disease.
    Maranhão RC; Leite AC
    Curr Pharm Des; 2015; 21(9):1196-204. PubMed ID: 25312729
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nicotinamide phosphoribosyltransferase inhibition reduces intraplaque CXCL1 production and associated neutrophil infiltration in atherosclerotic mice.
    Nencioni A; da Silva RF; Fraga-Silva RA; Steffens S; Fabre M; Bauer I; Caffa I; Magnone M; Sociali G; Quercioli A; Pelli G; Lenglet S; Galan K; Burger F; Vázquez Calvo S; Bertolotto M; Bruzzone S; Ballestrero A; Patrone F; Dallegri F; Santos RA; Stergiopulos N; Mach F; Vuilleumier N; Montecucco F
    Thromb Haemost; 2014 Feb; 111(2):308-22. PubMed ID: 24196571
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Cultured cell systems for revelation of new drugs antiatherosclerotic effects and their mechanisms investigation].
    Orekhov AN; Sobenin IA; Orekhova VA; Mel'nichenko AA; Miasoedova VA; Mukhamedova NM; Martirosian DM; Pshezhetskiĭ AV; Karagodin VP
    Patol Fiziol Eksp Ter; 2012; (1):33-9. PubMed ID: 22629858
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cholesterol efflux and reverse cholesterol transport.
    Favari E; Chroni A; Tietge UJ; Zanotti I; Escolà-Gil JC; Bernini F
    Handb Exp Pharmacol; 2015; 224():181-206. PubMed ID: 25522988
    [TBL] [Abstract][Full Text] [Related]  

  • 35. AGI-1067: a multifunctional phenolic antioxidant, lipid modulator, anti-inflammatory and antiatherosclerotic agent.
    Sundell CL; Somers PK; Meng CQ; Hoong LK; Suen KL; Hill RR; Landers LK; Chapman A; Butteiger D; Jones M; Edwards D; Daugherty A; Wasserman MA; Alexander RW; Medford RM; Saxena U
    J Pharmacol Exp Ther; 2003 Jun; 305(3):1116-23. PubMed ID: 12626663
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Heat shock protein 90 inhibitors attenuate inflammatory responses in atherosclerosis.
    Madrigal-Matute J; López-Franco O; Blanco-Colio LM; Muñoz-García B; Ramos-Mozo P; Ortega L; Egido J; Martín-Ventura JL
    Cardiovasc Res; 2010 May; 86(2):330-7. PubMed ID: 20154064
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pleiotropic effects of ezetimibe: do they really exist?
    Kalogirou M; Tsimihodimos V; Elisaf M
    Eur J Pharmacol; 2010 May; 633(1-3):62-70. PubMed ID: 20152830
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Contribution of neovascularization and intraplaque haemorrhage to atherosclerotic plaque progression and instability.
    Chistiakov DA; Orekhov AN; Bobryshev YV
    Acta Physiol (Oxf); 2015 Mar; 213(3):539-53. PubMed ID: 25515699
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cyclodextrin polymer improves atherosclerosis therapy and reduces ototoxicity.
    Kim H; Han J; Park JH
    J Control Release; 2020 Mar; 319():77-86. PubMed ID: 31843641
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Peroxisome proliferator-activated receptor δ agonist GW1516 attenuates diet-induced aortic inflammation, insulin resistance, and atherosclerosis in low-density lipoprotein receptor knockout mice.
    Bojic LA; Burke AC; Chhoker SS; Telford DE; Sutherland BG; Edwards JY; Sawyez CG; Tirona RG; Yin H; Pickering JG; Huff MW
    Arterioscler Thromb Vasc Biol; 2014 Jan; 34(1):52-60. PubMed ID: 24158519
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.